These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655 [TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740 [TBL] [Abstract][Full Text] [Related]
6. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease. Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642 [TBL] [Abstract][Full Text] [Related]
7. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965 [TBL] [Abstract][Full Text] [Related]
8. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230 [TBL] [Abstract][Full Text] [Related]
9. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928 [TBL] [Abstract][Full Text] [Related]
10. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. Liot G; Zala D; Pla P; Mottet G; Piel M; Saudou F J Neurosci; 2013 Apr; 33(15):6298-309. PubMed ID: 23575829 [TBL] [Abstract][Full Text] [Related]
11. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Brown TB; Bogush AI; Ehrlich ME Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688 [TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740 [TBL] [Abstract][Full Text] [Related]
14. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655 [TBL] [Abstract][Full Text] [Related]
16. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice. Jeon J; Kim W; Jang J; Isacson O; Seo H Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602 [TBL] [Abstract][Full Text] [Related]
17. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. Zuccato C; Belyaev N; Conforti P; Ooi L; Tartari M; Papadimou E; MacDonald M; Fossale E; Zeitlin S; Buckley N; Cattaneo E J Neurosci; 2007 Jun; 27(26):6972-83. PubMed ID: 17596446 [TBL] [Abstract][Full Text] [Related]
18. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease. Ma Q; Yang J; Li T; Milner TA; Hempstead BL Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324 [TBL] [Abstract][Full Text] [Related]
19. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077 [TBL] [Abstract][Full Text] [Related]
20. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease. Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]